MedTrace Logo

Non-malarial Febrile Illness in Children in Areas of Perennial Malaria Transmission

NCT01043744 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1000

Last updated 2013-03-11

No results posted yet for this study

Summary

To evaluate the causes of non-malarial febrile illness in children living in an area of perennial malaria transmission and to determine if these children who test negative for malaria by rapid diagnostic test receive any benefit from antimalarial therapy.

Conditions

  • Malaria
  • Non-malarial Febrile Illness

Interventions

DRUG

Artemether-Lumefantrine

Artemether-lumefantrine (Coartem; Novartis) administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine at a dosage of: * 1 tablet (for patients weighing 5-14 kg) * 2 tablets (for patients weighing 15-24 kg)

Sponsors & Collaborators

Principal Investigators

  • Meredith L McMorrow, MD, MPH · Centers for Disease Control and Prevention

  • S. Patrick Kachur, MD, MPH · Centers for Disease Control and Prevention

  • Larry Slutsker, MD · Centers for Disease Control and Prevention

  • Saumu Ahmed, MD · Ifakara Health Institute

  • Salim MK Abdulla, MD, PhD · Ifakara Health Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Months
Max Age
59 Months
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2011-12-31
Completion
2011-12-31

Countries

  • Tanzania

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01043744 on ClinicalTrials.gov